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background: The human endometrium efﬁciently repairs each month after menstruation. The mechanisms involved in this repair
process remain undeﬁned. Aberrations in endometrial repair may lead to the common disorder of heavy menstrual bleeding. We hypothe-
sized that connective tissue growth factor (CTGF) is increased at the time of endometrial repair post-menses and that this increase is regu-
lated by prostaglandins (PGs) and hypoxic conditions present during menstruation.
methods and results: Examination of 41 endometrial biopsies from 5 stages of the menstrual cycle revealed maximal CTGF
mRNA expression (using quantitative RT–PCR) at menstruation and peak protein levels during the proliferative phase. CTGF was immuno-
localized to epithelial and stromal cells, with intense staining of occasional stromal cells during the proliferative phase. Dual immunohisto-
chemistry identiﬁed these cells as macrophages. Treatment of endometrial epithelial cells with 100 nM PGE2, PGF2a or hypoxia (0.5%
O2) revealed a signiﬁcant increase in CTGF mRNA expression (P, 0.01 for all, versus vehicle control). Cells treated simultaneously with
PGE2 and hypoxia revealed a synergistic increase in CTGF expression (P, 0.05 versus PGE2 or hypoxia alone) and maximal secreted
CTGF protein levels (P, 0.05 versus control).
conclusions: CTGF is increased in the human endometrium at the time of endometrial repair post-menses. The increase in CTGF
may be mediated by PG production and the transient hypoxic episode observed in the endometrium at menstruation.
Key words: menstruation / repair / prostaglandins / hypoxia / macrophage
Introduction
The human endometrium is an excellent physiological model of cyclical
tissue injury and repair. If pregnancy does not occur, the corpus
luteum regresses in the late secretory phase and progesterone levels
decline. This withdrawal of progesterone triggers an inﬂammatory re-
sponse in the endometrium, which culminates in the menstrual shed-
ding of the functional endometrial layer (Critchley et al., 2001; King
and Critchley, 2010). Subsequent repair is very efﬁcient, occurring
without scarring or loss of function. However, the precise mechanisms
involved remain poorly understood. Observational studies have shown
that endometrial repair begins on Day 2, during active bleeding, and
full coverage of the lumen is usually achieved by Day 6 (Ludwig and
Spornitz, 1991). In addition, the endometrium is shed in a piecemeal
fashion at menstruation with simultaneous repair occurring in adjacent
areas (Garry et al., 2009). These studies highlight that factors involved
in the initiation of endometrial repair ‘post-menses’ must be present at
the time of menses itself.
Connective tissue growth factor (CTGF) is a multifunctional
growth factor that is expressed at high levels during wound repair
and at sites of connective tissue formation (Igarashi et al., 1993).
Its biological effects include chemotaxis, differentiation, extracellular
matrix (ECM) production, angiogenesis, tumour growth, wound
healing and ﬁbrosis (Igarashi et al., 1993; Frazier et al., 1996;
Oemar et al., 1997; Hishikawa et al., 2000; Shimo et al., 2001;
Ivkovic et al., 2003). It is, therefore, an attractive candidate for
endometrial repair. CTGF protein and mRNA have previously
been detected in the human endometrium by immunohistochemistry
and northern blot analysis, respectively (Uzumcu et al., 2000). CTGF
was localized to epithelial and endothelial cells in proliferative and
secretory phase biopsies. Whereas, in contrast, endometrial
stromal cells were only stained after decidualization in the late secre-
tory phase (Uzumcu et al., 2000). Unfortunately, no menstrual phase
biopsies were included in this study, but the presence of CTGF in
the normal cycling endometrium suggests that it may facilitate
tissue repair and remodelling after menses.
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Premenstrual progesterone withdrawal increases levels of
cyclo-oxygenase (COX) 2 enzyme in the endometrium (Critchley
et al., 1999), which stimulates the synthesis of endometrial prosta-
glandins (PGs), including prostaglandin E2 (PGE2) and F2a (PGF2a).
PGF2a is emerging as a potential key player in the initiation of ex-
pression of endometrial repair factors. PGs have been demon-
strated to induce a host of endometrial angiogenic factors
including vascular endothelial growth factor, adrenomedullin, ﬁbro-
blast growth factor-2 and interleukin-8 (Keightley et al., 2010;
Maybin et al., 2011a,b,c). Functionally, PGF2a has been shown to
increase endometrial epithelial cell proliferation in culture (Milne
and Jabbour, 2003) and is known to induce vasoconstriction of
endometrial spiral arterioles (Baird et al., 1996). There is evidence
that this vasoconstriction results in a transient, local hypoxic insult
in the uppermost endometrial layer at menstruation (Critchley
et al., 2006; Fan et al., 2008).
We hypothesized that CTGF is increased at the time of endometrial
repair and regeneration and that this putative repair factor is regulated
by PGs and hypoxia.
Materials and Methods
Human endometrial tissue collection
Endometrial biopsies (n ¼ 41) were collected with a suction curette
(Pipelle, Laboratorie CCD, Paris, France) from women (median age: 42
years, range: 22–50) attending gynaecological out-patient departments
across National Health Service Lothian. All women reported regular men-
strual cycles (21–35 days) and no exogenous hormone exposure for 3
months prior to biopsy. Women with large ﬁbroids (.3 cm) or endomet-
riosis were excluded. Tissue was divided and (i) placed in RNA later, RNA
stabilization solution [Ambion (Europe) Ltd., Warrington, UK], (ii) ﬁxed in
neutral-buffered formalin for wax embedding and (iii) placed in phosphate-
buffered saline for in vitro culture. Biopsies were consistent for (i) histo-
logical dating using criteria of Noyes et al. (1950), (ii) reported last men-
strual period and (iii) serum progesterone and estradiol concentrations
at time of biopsy (Table I). Written consent was obtained from partici-
pants and ethical approval granted from Lothian Research Ethics
Committee.
Immunohistochemistry
Three micrometres of parafﬁn sections was dewaxed and rehydrated.
Antigen retrieval was undertaken by microwaving sections in a pH 6
antigen-retrieval buffer (Vector Laboratories, Peterborough, UK).
Endogenous peroxidase activity was blocked by 3% hydrogen peroxide.
Sections were sequentially incubated in avidin and biotin (Vector
Laboratories) and protein block (Dako, Cambridge, UK). Goat poly-
clonal CTGF antibody (Santa Cruz Biotechnology, CA, USA) was
applied overnight at 48C. Negative controls were incubated with
primary antibody pre-absorbed in antigen (CTGF peptide, Santa Cruz).
Biotinylated horse anti-goat secondary antibody was used at 1:200.
Avidin–biotin–peroxidase complex (ABC-Elite, Vector laboratories)
was applied for 30 min and liquid diaminobenzidine kit (Zymed Labora-
tories, San Francisco, CA, USA) used for detection. The reaction was
stopped with distilled water and the sections were counterstained
with haematoxylin, dehydrated and mounted with Pertex (Cellpath plc,
Hemel Hempstead, UK).
Dual staining immunohistochemistry
demonstrating co-localization of CD68 and
CTGF
Endometrial sections underwent dewaxing, rehydration, antigen retrieval
and treatment with 3% hydrogen peroxidase as above. Normal donkey
serum was used as a protein block and the sections were incubated
with mouse monoclonal CD68 (a pan-macrophage antigen) antibody
(Dako, Glostrup, Denmark) at a 1 in 1000 dilution overnight at 48C.
Donkey anti-mouse peroxidase secondary antibody (Abcam, Cambridge,
UK) at a 1:750 dilution was applied for 30 min followed by incubation
with TSATM ﬂuorescein tyramide system (Perkin Elmer, Waltham, MA,
USA) for 10 min. The sections were incubated with normal donkey
serum for 10 min followed by goat polyclonal CTGF antibody (Santa
Cruz Biotechnology) at a 1 in 100 dilution overnight at 48C. Alexa 546
donkey anti-goat secondary antibody (Invitrogen, Paisley, UK) was
applied for 1 h, followed by a 4′,6-diamidino-2-phenylindole stain (Sigma,
Dorset, UK) for 10 min. Sections were then mounted with permaﬂour
(Thermo Scientiﬁc, Waltham, MA, USA) and analysed with a Zeiss
LSM710 confocal microscope system.
Semi-quantitative histoscoring of
endometrial CTGF expression
Localization and intensity of immunostaining was evaluated blindly by two
independent observers using a semi-quantitative scoring system (Aas-
mundstad et al., 1992). The intensity of staining was graded with a three-
point scale (0 ¼ no staining, 1 ¼ mild staining and 2 ¼ strong staining).
This was applied to the glands and stromal cells (n ¼ 41), as well as the
surface epithelium where visualized (n ¼ 36). The percentage of tissue
in each intensity scale was recorded. A value was derived for each of
the cellular compartments by using the sum of these percentages after
multiplication by the intensity of staining.
.............................................................................................................................................................................................
Table I Human endometrial biopsies used in this study.
Stage of cycle Number of biopsies Mean serum estradiol levels, pmol/l (range) Mean serum progesterone, nmol/l (range)
Menstrual 8 192.25 (55–514) 3.71* (1.24–10.59)
Proliferative 11 441.18 (79–1105) 2.81* (0.97–7.10)
Early secretory 7 497.50 (289–841) 59.60 (23.2–112.91)
Mid-secretory 8 638.00 (242–1949) 64.30 (25.47–114.53)
Late secretory 7 318.22 (59.09–819) 8.22* (1.06–16.95)
*Signiﬁcantly different from early and mid-secretory levels, P, 0.05.
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Culture of endometrial cells
Human Ishikawa endometrial adenocarcinoma cells (European collection
of cell culture, Centre for Applied Microbiology, Wiltshire, UK) were
stably transfected with the PGF2a receptor (FPS cells) or a PGE2 receptor
(EP2S cells) as previously described (Sales et al., 2004). To determine the
effect of PGE2/F2a and/or hypoxic conditions on CTGF expression,
4 × 105 FPS or EP2S cells were seeded in 6-well plates in Dulbecco’s
modiﬁed eagle’s medium F-12 supplemented with 10% fetal calf serum,
1% penicillin/streptomycin and 200 mg/ml G418. The following day,
cells were incubated in serum-free culture medium containing 8.4 mM
indomethacin (COX enzyme inhibitor) for at least 16 h. Cells were then
treated with vehicle or 100 nM PGE2/F2a and placed in normoxia (21%
O2, 5% CO2, 378C) or a sealed hypoxic chamber (0.5% O2, 5% CO2,
378C) for 2, 4, 6, 8 or 24 h.
Culture of endometrial tissue explants
Endometrial biopsies (proliferative n ¼ 3, secretory n ¼ 3) were divided
into four explants of equal size and incubated on raised platforms in
24-well plates, just covered with serum-free RPMI 1640 medium and
8.4 mM indomethacin for 16 h. One explant from each biopsy was then
treated with vehicle in normoxia, one with 100 nM PGF2a in normoxia,
one with 100 mM PGE2 in normoxia and one with vehicle in hypoxia for
24 h.
Quantitative RT–PCR
Expression of CTGF in endometrial tissue and cells was determined by
quantitative RT–PCR (QRT–PCR, Taqman) analysis. Total RNA from
cells and endometrial biopsies was extracted using the RNeasey Mini Kit
(Qiagen Ltd, Sussex, UK) according to manufacturer’s instructions. DNA
contamination of samples was removed by DNA digestion during RNA
puriﬁcation. RNA samples were reverse transcribed using MgCl2
(5.5 mM), deoxynucleotide triphosphates (0.5 mM each), random hexam-
ers (2.5 mM), ribonuclease inhibitor (0.4 U/ml) and multiscribe reverse
transcriptase (1.25 U/ml; all from PE Biosystems, Warrington, UK).
Total RNA of 200 ng was added. A tube with no reverse transcriptase
and a further tube with water were included as controls. To measure
cDNA levels, a reaction mix was prepared containing Taqman buffer
(5.5 mM MgCl2, 200 mM dATP 200 mM dCTP, 200 mM dGTP and
400 mM deoxyuridine triphosphate), ribosomal 18S primers/probe
(Applied Biosystems, Warrington, UK) and speciﬁc forward and reverse
primers and probes: CTGF forward primer 5′-TGCACCGCCAAA-
GATGGT-3′, reverse primer 5′-GGCACGTGCACTGGTACTTG-3′,
probe 5′-CTCCCTGCATCTTCGGTGGTACGGT-3′ was added for
each PCR reaction. Negative controls (water instead of cDNA) were
included in each run. PCR was carried out using an ABI Prism 7900
(Applied Biosystems). Samples were analysed in triplicate using Sequence
Detector version 2.3 (PE Biosystems), using the comparative threshold
method. Expression of target mRNA was normalized to RNA loading
for each sample using the 18S ribosomal RNA as an internal standard.
There was no signiﬁcant change in 18S rRNA expression between nor-
moxic and hypoxic conditions.
CTGF protein quantiﬁcation
CTGF secreted protein concentrations were measured using a human
CTGF ELISA development kit (PeproTech, London, UK) according to
manufacturer’s instructions. Colour development was measured on an
enzyme-linked immunosorbent assay plate reader at 405 nm. The
minimum detectable concentration of CTGF was 63 pg/ml. There was
no signiﬁcant cross-reactivity for human bone morphogenetic protein-4,
CTGF-L/WNT inducible signalling pathway (WISP)-2, cystine rich
protein-61, insulin-like growth factor (IGF)-I, IGF-II, IGF-BP1, nephroblas-
toma overexpressed gene, transforming growth factor-b, WISP-1 or
WISP-3.
Statistics
For endometrium from across the menstrual cycle, mRNA results were
expressed as the quantity relative to a comparator sample of RNA from
the liver. Signiﬁcant differences in mRNA and protein were determined
using Kruskal–Wallis non-parametric test with Dunn’s multiple compari-
son post-test (Prism, version 4.02, GraphPad Software, Inc., San Diego,
CA, USA). For cell culture, mRNA results are expressed as fold increase,
where relative expression of mRNA after treatment was divided by the
relative expression after vehicle treatment. Data are presented as mean
+ SEM and signiﬁcant differences among raw data determined using
one-way analysis of variance with Tukey’s multiple comparison test. A
value of P, 0.05 was considered signiﬁcant.
Results
Endometrial CTGF mRNA expression
Endometrial CTGF mRNA expression varied signiﬁcantly across the
menstrual cycle (P ¼ 0.0032; Fig. 1). Maximal CTGF mRNA expres-
sion was present in endometrium from the menstrual phase, with
levels signiﬁcantly greater than those found during the early (P,
0.01), mid- (P, 0.05) and late (P, 0.05) secretory phases.
Endometrial CTGF protein localization
CTGF was immunolocalized to the cytoplasm of surface epithelial,
glandular epithelial, stromal and vascular endothelial cells or
Figure 1 CTGF mRNA expression in human endometrial tissue
from across the menstrual cycle. Values of CTGF are presented as
relative to the 18S ribosomal RNA internal standard and to a
sample of RNA from the liver as a comparator. M, menstrual; P, pro-
liferative; ES, early secretory; MS, mid-secretory; LS, late secretory;
KW, Kruskal–Wallis statistical test (*P, 0.05, **P, 0.01). Box
and whisker plots: each box represents the 25th and 75th percentiles
and the whiskers are the 10th and 90th percentiles. Horizontal lines
represent the median.
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endometrium from the menstrual and proliferative phases (Fig. 2A–
D). There was an obvious reduction in staining intensity during the se-
cretory phase (Fig. 2E and F). Intense staining of occasional cells in the
stromal compartment of proliferative endometrium was observed
(Fig. 2H). These cells were usually found in close proximity to the
endometrial vasculature. Semi-quantitative scoring of immunohisto-
chemical staining revealed signiﬁcantly greater staining of the glandular
epithelial, surface epithelial and stromal cells in proliferative phase
endometrium when compared with mid-secretory endometrium
(P, 0.001, P, 0.001, P, 0.01 respectively; Fig. 3).
Stromal CTGF was immunolocalized to
macrophage cells
Proliferative endometrial tissue was subjected to dual staining immu-
nohistochemistry for CTGF and CD68 (a pan-macrophage antigen).
This revealed that the occasional stromal cells that were positively
stained for CTGF also expressed CD68 (Fig. 4). Glandular epithelial
cells were positively stained for CTGF but did not reveal dual staining
for CD68.
CTGF expression was regulated by PGs
and hypoxia
A time course experiment in EP2S cells revealed a signiﬁcant increase
in CTGF mRNA expression on treatment with 100 nM PGE2 com-
pared with vehicle at 4 and 8 h (P, 0.01) (Fig. 5A). Hypoxic condi-
tions (0.5% O2) also signiﬁcantly increased CTGF mRNA expression
in EP2S cells at 2 h versus normoxic controls (P, 0.001; Fig. 5B).
Interestingly, in prolonged hypoxic conditions this up-regulation did
not take place. When cells were treated with both PGE2 and
hypoxia for 2 h, there was a synergistic increase in CTGF mRNA ex-
pression that was signiﬁcantly greater than that seen with either treat-
ment alone (P, 0.05; Fig. 5C). As maximal CTGF mRNA expression
occurred between 2 and 4 h, the amount of CTGF protein secreted
into culture supernatants was assessed by ELISA at a 6 h time point.
CTGF secreted protein was below the level of detection of the
ELISA in vehicle-treated cells but was signiﬁcantly increased when
EP2S cells were co-treated with PGE2 and hypoxia (P, 0.05; Fig. 5D).
Treatment of FPS cells with 100 nM PGF2a for 6 h resulted in signiﬁ-
cant up-regulation of CTGF mRNA expression versus vehicle-treated
cells (P, 0.001; Fig. 5E). As in EP2S cells, hypoxic conditions did not
signiﬁcantly increase CTGF mRNA expression at 6 h in FPS cells
(Fig. 5E). Secreted protein levels in culture supernatants at 24 h
demonstrated signiﬁcant increases in CTGF protein over controls
after treatment with PGF2a (P, 0.001) (Fig. 5F).
Treatment of endometrial explants from the proliferative phase
showed a modest increase in CTGF mRNA expression when explants
were placed in hypoxic conditions (P, 0.05; Fig. 5G). Explants from
the secretory phase displayed a more marked increase in CTGF
mRNA expression in hypoxic conditions (P, 0.001; Fig. 5H). No sig-
niﬁcant increase in CTGF mRNA was observed when explants were
treated with PGs, regardless of cycle stage.
Discussion
These data demonstrate maximal expression of CTGF in the human
endometrium during the menstrual and proliferative phases; a time
consistent with endometrial repair and regeneration. In addition,
CTGF protein is localized to glandular epithelial cells and macrophages
in the stromal cell compartment. Furthermore, this paper describes
signiﬁcant increases in CTGF mRNA and secreted protein in endo-
metrial cells treated with PGs and/or hypoxia. These data provide a
potential mechanism for the up-regulation of CTGF during the time
of endometrial repair associated with menstruation.
The location and timing of endometrial
repair
The data presented herein were generated from examination of endo-
metrial biopsies collected with an endometrial sampler. The majority
of endometrium collected with this method is from the functional
layer. As this layer is sloughed off during menses, it has hitherto
been assumed that endometrial repair was governed by factors
present in the basal layer. An important recent study of menstrual
endometrium from the superﬁcial layer has revealed an increase in ex-
pression of genes associated with ECM biosynthesis in stromal cells
from this upper layer when compared with those from the basal
layer (Gaide Chevronnay et al., 2009). This suggests that fragments
of the functional layer of endometrium do make an active contribution
to the endometrial repair process. Further, recent laser capture
microdissection techniques have identiﬁed that both the stromal and
epithelial cell compartments have an active role in this repair
process (Gaide Chevronnay et al., 2010).
Hysteroscopic, histological and scanning electron microscopy
studies have documented the time course of endometrial repair.
The endometrium is shed in a piecemeal fashion and repair com-
mences in delineated areas while shedding occurs simultaneously in
adjacent areas (Garry et al., 2009). Therefore, examination of endo-
metrial repair factors during the menstrual phase is essential when
examining the process of repair in the context of menstruation.
CTGF and endometrial repair
CTGF is a member of the CCN family of growth regulators (Brigstock,
2002) and has a putative role in endometrial repair. Data herein
demonstrate maximal CTGF mRNA expression in menstrual phase
endometrium. CTGF protein showed intensely positive immunohisto-
chemical staining during the proliferative phase, which was signiﬁcantly
elevated in glandular epithelial, surface epithelial and stromal cells
when compared with the mid-secretory phase. This is the ﬁrst de-
scription of CTGF mRNA expression and protein staining intensity
in human endometrium from all stages of the menstrual cycle, includ-
ing at menstruation. A previous study immunolocalized human endo-
metrial CTGF to epithelial, stromal and endothelial cells but did not
examine endometrium from the menstrual phase (Uzumcu et al.,
2000). In contrast to ﬁndings described herein, Uzumcu et al (2000)
found minimal staining of stromal cells in proliferative tissue and main-
tenance of epithelial staining throughout the secretory phase. These
differences may be explained by varying antibody speciﬁcities or by
the classiﬁcation of endometrial tissue studied. We have carefully
staged the tissues used in this study based on reported day of cycle,
serum ovarian hormone levels on the day of biopsy and histological
dating. Other members of the CCN family also show signiﬁcant
variation in human endometrial expression across the cycle. The
pro-angiogenic factor cysteine rich protein 61 (CYR61) was found
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to be signiﬁcantly elevated during menses (Gashaw et al., 2008) and
authors proposed it contributes to repair, growth and maturation of
the endometrial vasculature after menstruation.
The mechanism by which CTGF exerts its effects remains undeﬁned
at a molecular level, therefore examination of receptor expression for
this factor was not possible. CYR61 (a member of the CNN family)
has been shown to bind to integrin anb3 to mediate cell adhesion
and migration (Kireeva et al., 1998) and CTGF may elicit its biological
effects in a similar manner. Alternatively, it has been proposed that the
CCN family may not signal exclusively via cell surface receptors but
rather are a component of the ECM, bridging the functional gap
between structural and active molecules (Lau and Lam, 1999).
Figure 2 CTGF immunohistochemical staining in human endometrium from across the menstrual cycle: (A and B) menstrual phase endometrium,
(C and D) proliferative phase endometrium, (E and F) mid-secretory phase endometrium, (G) negative control menstrual endometrium, incubated
with the primary antibody pre-absorbed with blocking peptide and (H) intense staining of occasional cells (arrows) in the stromal cell compartment of
proliferative endometrium. Scale bar ¼ 50 mm. Arrows, endothelial cells; GE, glandular epithelial cells; St, stromal compartment.
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Other components of the ECM are known to have a fundamental role
in the repair process and have a similar endometrial pattern of expres-
sion to that of CTGF. Fibronectin (FN) is a large glycoprotein that
interacts with speciﬁc integrins to enhance cell adhesion and migration
during wound repair (Kim et al., 1992). Utilizing the ovariectomized
rhesus macaque model, Cao et al. (2007) demonstrated a 50-fold in-
crease in FN expression from the secretory to the menstrual phase
alongside a 17-fold increase in its receptor, integrin-b1. Real-time
PCR, in situ hybridization and immunohistochemistry conﬁrmed
these ﬁndings and localized the increase in FN expression to the
uppermost endometrial glands and luminal epithelium. Signiﬁcant
increases in adhesive molecules, such as CTGF and FN, in the func-
tional layer of the endometrium at this time implicate involvement in
surface healing post-menstruation.
Interestingly, we observed intense CTGF immunostaining of occa-
sional stromal cells during the proliferative phase. Dual staining immu-
nohistochemistry identiﬁed these cells as macrophages. Macrophages
have a fundamental role in the inﬂammatory response and are often
found at sites of intense tissue remodelling. They have been detected
in the endometrium throughout the menstrual cycle (Bonatz et al.,
1992) with a signiﬁcant inﬂux during the late secretory phase
(Kamat and Isaacson, 1987). The importance of endometrial leuko-
cytes in post-menstrual repair has been demonstrated in the mouse
model of menstruation. Neutrophil depletion using the antibody
RB6-8C5 markedly delayed endometrial repair when examined 48 h
after progesterone withdrawal versus control animals (Kaitu’u-Lino
et al., 2007). The role of macrophages during endometrial repair is
still to be fully deﬁned but macrophage depletion in the mouse
model of endometriosis suggests a crucial role in growth and vascular-
ization (Bacci et al., 2009). Detection of CTGF within endometrial
macrophages is thought to be of an endocytotic nature from the sur-
rounding environment where it potentially acts as a chemoattractant
to peripheral mononuclear cells (Cicha et al., 2005). CTGF may be
involved in the inﬂux of macrophages to the endometrium during
the latter stages of the menstrual cycle. There is recent evidence sug-
gesting communication between macrophages and stromal cells in the
human endometrium (Eyster et al., 2010). Endometrial stromal cells
co-cultured with macrophage cell supernatant demonstrated signiﬁ-
cantly increased expression of CTGF over those cultured with
vehicle. Moreover, this response was found to be abrogated in the
presence of estradiol and progesterone. Hence, endometrial macro-
phages may contribute to the signiﬁcant increase in stromal cell ex-
pression of CTGF at the time of menstruation, when ovarian
hormone levels are low.
Hypoxia and the induction of repair
Herein we have demonstrated a signiﬁcant increase in CTGF mRNA
after exposure of endometrial epithelial cells and endometrial tissue
explants to hypoxic conditions. The timing of increased CTGF in re-
sponse to hypoxia was different in endometrial cells and tissue
explants, with cells demonstrating a rapid response and tissue main-
taining increased CTGF expression at 24 h. This may reﬂect the het-
erogeneous cell population that constitutes endometrial tissue.
Tissue explants allow maintenance of cell–cell communication in
vitro, mimicking the in vivo scenario more accurately than single cell
culture.
It is postulated that a period of transient hypoxia occurs in vivo in
the uppermost endometrial zones as spiral arterioles constrict follow-
ing progesterone withdrawal. An early study in the rhesus monkey
(Markee, 1940) revealed intense endometrial vasoconstriction, tissue
necrosis and menstruation following progesterone withdrawal. More
recently, the use of pimonidazole (hydroxyprobew), a marker of
oxygen partial pressures ,10 mmHg, in the mouse model identiﬁed
the presence of hypoxia during simulated menstruation (Fan et al.,
Figure 3 Semi-quantitative scoring of human endometrial CTGF
immunohistochemical staining across the menstrual cycle. (A) Glan-
dular epithelial cells, (B) surface epithelial cells and (C) the stromal
cell compartment. KW, Kruskal–Wallis statistical test (*P, 0.05,
**P, 0.01, ***P, 0.001).
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2008). In contrast, negligible levels of pimonidazole were observed by
Day 5 after progesterone withdrawal. Furthermore, markers of tissue
hypoxia (CAIX and hypoxia inducible factor-1a) have been detected
immunohistochemically in the human endometrium during menstru-
ation, with a distinct reduction in staining of both markers after
cycle Day 5 (Critchley et al., 2006; Punyadeera et al., 2006).
Prostaglandins and the induction of repair
We also demonstrate signiﬁcant increases in CTGF mRNA and
protein expression in endometrial cells after incubation with PGE2
and PGF2a. These results contrast with ﬁndings in rat ﬁbroblast cells
and human airway smooth muscle cells, where PGE2 treatment
decreased CTGF mRNA expression (Yu et al., 2002; Burgess et al.,
2006); highlighting the cell and tissue-speciﬁc nature of CTGF induc-
tion. We have demonstrated a synergistic increase in CTGF mRNA
expression in endometrial cells treated with PGE2 and hypoxia simul-
taneously. Both PGE2 and PGF2a have previously been shown to in-
crease endometrial epithelial cell CYR61 mRNA expression
(Gashaw et al., 2008). Furthermore, a synergistic increase with both
hypoxia and PGE2 was also demonstrated for this other member of
the CCN family. Of note, CTGF mRNAwas not increased in response
to PGE2/F2a in endometrial tissue explants examined herein. This may
be explained by a lack of FP receptors (the PGF2a receptor) in human
endometrial stromal cells (Milne and Jabbour, 2003), which may mask
any epithelial increase in CTGF mRNA in whole tissue explants. Alter-
natively, the response of endometrial tissue to PG exposure in vitro
may occur at a different time point. Owing to the limitations of
human tissue availability, time-course experiments could not be
performed.
As hypoxic conditions and increased PG synthesis have been
demonstrated in the premenstrual endometrium following progester-
one withdrawal, these factors may have an important role in the induc-
tion of CTGF. Their independent and synergistic actions may provide
a robust mechanism for the stimulation of endometrial repair.
Transforming growth factor (TGF)-b is well established as a transcrip-
tional regulator of CTGF in other cell types (Harlow et al., 2002;
Higgins et al., 2004). The role of TGF-b and other inﬂammatory med-
iators in endometrial CTGF expression remains to be determined.
Conclusions
This paper describes maximal CTGF levels in the menstrual and pro-
liferative endometrium; a time consistent with endometrial repair. We
Figure 4 Dual staining immunolocalization of CTGF and CD68 in endometrium from the proliferative phase: (A) nuclei staining in blue, (B) CD68
staining in green, (C) CTGF staining in red and (D) dual staining for CD68 (green) and CTGF (red) showing co-localization of CTGF in macrophage
cells.
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Figure 5 The regulation of CTGF by hypoxia and prostglandins. (A) CTGF mRNA expression in EP2S cells treated with vehicle or 100 nM PGE2 for
up to 48 h in normoxic conditions (n ¼ 3). (B) CTGF mRNA expression in EP2S cells cultured in normoxic and hypoxic conditions for up to 48h
(n ¼ 3). (C) CTGF mRNA expression in EP2S cells treated with 100 nM PGE2 and/or hypoxia for 2 h (n ¼ 3). (D) Secreted CTGF protein levels
in EP2S cell culture supernatant at 6 h (n ¼ 3). (E) CTGF mRNA expression in FPS cells treated with 100 nM PGE2 and/or hypoxia for 6 h
(n ¼ 3). (F) Secreted CTGF protein levels in FPS cell culture supernatant at 24 h (n ¼ 3). (G) CTGF mRNA in endometrial tissue explants from
the proliferative phase treated with vehicle, 100 nM PGE2, 100 nM PGF2a or hypoxia (n ¼ 3). (H) CTGF mRNA in endometrial tissue explants
from the secretory phase treated with vehicle, PGF2a, PGE2 or hypoxia (n ¼ 3). N, normoxia (21% O2), H, hypoxia (0.5% O2); V, ethanol
vehicle; PG, prostaglandin (*P, 0.05, **P, 0.01, ***P, 0.01). Fold changes are relative to ﬁndings in vehicle-treated controls in normoxic conditions.
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describe the induction of CTGF by PGE2, PGF2a and hypoxic condi-
tions and suggest these factors have a role in the perimenstrual endo-
metrium to up-regulate CTGF expression for endometrial repair.
Further studies are required to determine if aberrations in perimenstr-
ual PG production or vasoconstriction lead to decreased CTGF levels
and delayed repair, resulting in the clinical complaint of heavy or pro-
longed menstrual bleeding.
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